Genialis AI platform speeds identification of biomarkers
Cancer trials that stratify patients using biomarkers increase their likelihood of proceeding to the next phase more than 500% compared to trials run without biomarkers, Canadian researchers recently determined, and biotech companies have invested heavily in identifying new biomarkers for a wide range of applications. Genialis Inc. has tackled the problem of huge investment in biomarkers with little return by developing a platform that combines artificial intelligence and machine learning.
Read the whole article on BioWorld
(published on Jan 5, 2022, author: Annette Boyle)